# Assessment of Anti-RANKL Antibody in Post-menopausal Women

> **NCT03242512** · PHASE1 · UNKNOWN · sponsor: **Jiangsu T-Mab Biopharma Co.,Ltd** · enrollment: 24 (estimated)

## Conditions studied

- Osteoporosis

## Interventions

- **BIOLOGICAL:** TK006

## Key facts

- **NCT ID:** NCT03242512
- **Lead sponsor:** Jiangsu T-Mab Biopharma Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-08-07
- **Primary completion:** 2018-12-30
- **Final completion:** 2018-12-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2018-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03242512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03242512, "Assessment of Anti-RANKL Antibody in Post-menopausal Women". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03242512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*